- 首頁
- 科研細胞
- 藥靶模型
-
診斷試劑
腫瘤早篩甲基化標準品
遺傳性基因標準品
優(yōu)生優(yōu)育標準品
HLA標準品
數(shù)字PCR
- 技術(shù)服務(wù)
- 新聞中心
- 資源中心
- 關(guān)于我們
- 聯(lián)系我們
藥靶模型
Drug Target Model
CBP73229
I. Introduction | |
Cell Line Name: |
CSF1R(CSF1 Dependent)/BaF3 |
Host Cell: |
Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: |
Monitor the CSF1R/MAPK/ERK signaling pathway activity and SRF-mediated activity. Screen for activators or inhibitors of the CSF1R/MAPK/ERK signaling pathway. |
Freeze Medium: |
90% FBS+10% DMSO
|
Complete Culture Medium: |
RPMI-1640+10%FBS+0.1ug/ml M-CSF
|
Mycoplasma Status: |
Negative |
II. Background | |
CSF1R is activated by either of two cytokines, CSF1 (MCSF; CSF-1) and IL-34 (IL34), causing homodimerization and activation of downstream kinase activity. CSF1R is expressed on the surface of monocytes and macrophages, and its activation controls the growth, function, and differentiation of macrophages. This interaction is used by numerous cancer types, such as diffuse-type tenosynovial giant cell tumors (dt-GCT), to evade the immune system. By overexpressing the cytokine CSF1, these cells drive the development and survival of Tumor-Associated Macrophages (TAMs), which in turn suppress the local immune response to the cancer. |
|
III. Representative Data | |
1.Anti-proliferation assay
Figure 2. Anti-proliferation assay of two reference compounds on the CSF1R(CSF1 Dependent)/BaF3 Stable Cell Line. |